Granulocyte colony-stimulating factor (G-CSF) is produced endogenously by several cell types, including monocytes, fibroblasts, and endothelial cells, primarily in response to infection or tissue injury. Its principal physiological role is to regulate the proliferation, differentiation, and functional activation of neutrophil precursors in the bone marrow, maintaining baseline circulating neutrophil counts and mounting a rapid response to immunological challenge.
Filgrastim is a non-glycosylated recombinant analogue of the endogenous protein, produced in Escherichia coli via recombinant DNA technology. It differs from the native molecule by a single N-terminal methionine residue and by the absence of O-linked glycosylation, yet retains comparable receptor-binding affinity and biological activity. The molecular weight of filgrastim is approximately 18.8 kDa. It binds selectively to the G-CSF receptor (CSF3R), a single-chain transmembrane protein expressed predominantly on haematopoietic progenitor cells and mature neutrophils, triggering downstream JAK/STAT and MAPK signalling cascades.
In Australia, filgrastim is a prescription-only medicine listed on the Australian Register of Therapeutic Goods (ARTG) and regulated under Schedule 4 of the Poisons Standard. Approved clinical indications, as assessed by the Therapeutic Goods Administration (TGA), include reduction of neutropenia duration and associated febrile complications following cytotoxic chemotherapy, treatment of severe chronic neutropenia, and mobilisation of haematopoietic progenitor cells for peripheral blood stem cell collection. PBS-listed presentations are subject to specific prescribing criteria and Authority requirements.
Filgrastim should not be conflated with unapproved peptide preparations sometimes marketed outside regulated channels. The TGA has stated that supplying biological or peptide products without valid ARTG registration or an appropriate exemption is illegal in Australia and may expose suppliers and recipients to significant legal and safety risks. No therapeutic claims may be made in relation to unapproved peptide formulations.
Sources: